$599

Denali Sells PRV For $195M; New China-Based UBT251 Obesity Study

Two cardiometabolic-related news items have been observed: Denali Therapeutics agreed to sell its PRV (view press release), and The United Laboratories posted a new Ph3 China-based UBT251 obesity study on CT.gov (view CT.gov record). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here